KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC
Makaleler > Özet · 2021
Yazarlar: J. Cortes, D. W. Cescon, H. S. Rugo, S-A. Im, M. Md Yusof, C. Gallardo, O. Lipatov, C. H. Barrios, J. Perez-Garcia, H. Iwata, N. Masuda, M. Torregroza Otero, Erhan GÖKMEN, S. Loi, Z. Guo, X. Zhou, V. Karantza, W. Pan, P. Schmid
ANNALS OF ONCOLOGY, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2021, cilt 32, ss S1289-S1290